Njiaju, U O <br/><br/>
Capecitabine and oxaliplatin in combination as first- or second-line therapy for metastatic breast cancer: a Wisconsin Oncology Network trial.  [electronic resource] 

 -  Cancer chemotherapy and pharmacology  Mar 2013 
 - 613-8 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1432-0843 
<br/><br/><label>Standard No.: </label>10.1007/s00280-012-2044-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibiotics, Antineoplastic--administration & dosage<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Capecitabine<br/>Confidence Intervals<br/>Deoxycytidine--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis--drug therapy<br/>Organoplatinum Compounds--administration & dosage<br/>Oxaliplatin<br/>Young Adult